333 related articles for article (PubMed ID: 20333455)
1. Targeting anticancer drugs to tumor vasculature using cationic liposomes.
Abu Lila AS; Ishida T; Kiwada H
Pharm Res; 2010 Jul; 27(7):1171-83. PubMed ID: 20333455
[TBL] [Abstract][Full Text] [Related]
2. Recent advances in tumor vasculature targeting using liposomal drug delivery systems.
Abu Lila AS; Ishida T; Kiwada H
Expert Opin Drug Deliv; 2009 Dec; 6(12):1297-309. PubMed ID: 19780711
[TBL] [Abstract][Full Text] [Related]
3. Fighting cancer: from the bench to bedside using second generation cationic liposomal therapeutics.
Campbell RB; Ying B; Kuesters GM; Hemphill R
J Pharm Sci; 2009 Feb; 98(2):411-29. PubMed ID: 18563780
[TBL] [Abstract][Full Text] [Related]
4. Sequential administration with oxaliplatin-containing PEG-coated cationic liposomes promotes a significant delivery of subsequent dose into murine solid tumor.
Abu Lila AS; Doi Y; Nakamura K; Ishida T; Kiwada H
J Control Release; 2010 Mar; 142(2):167-73. PubMed ID: 19861140
[TBL] [Abstract][Full Text] [Related]
5. Oxaliplatin encapsulated in PEG-coated cationic liposomes induces significant tumor growth suppression via a dual-targeting approach in a murine solid tumor model.
Abu Lila AS; Kizuki S; Doi Y; Suzuki T; Ishida T; Kiwada H
J Control Release; 2009 Jul; 137(1):8-14. PubMed ID: 19285528
[TBL] [Abstract][Full Text] [Related]
6. Ligand-targeted liposomes for cancer treatment.
Sapra P; Tyagi P; Allen TM
Curr Drug Deliv; 2005 Oct; 2(4):369-81. PubMed ID: 16305440
[TBL] [Abstract][Full Text] [Related]
7. Characterization of cationic liposome formulations designed to exhibit extended plasma residence times and tumor vasculature targeting properties.
Ho EA; Ramsay E; Ginj M; Anantha M; Bregman I; Sy J; Woo J; Osooly-Talesh M; Yapp DT; Bally MB
J Pharm Sci; 2010 Jun; 99(6):2839-53. PubMed ID: 20091826
[TBL] [Abstract][Full Text] [Related]
8. Tumor vasculature targeting following co-delivery of heparin-taurocholate conjugate and suberoylanilide hydroxamic acid using cationic nanolipoplex.
Kim JY; Shim G; Choi HW; Park J; Chung SW; Kim S; Kim K; Kwon IC; Kim CW; Kim SY; Yang VC; Oh YK; Byun Y
Biomaterials; 2012 Jun; 33(17):4424-30. PubMed ID: 22425551
[TBL] [Abstract][Full Text] [Related]
9. Intracellular targeting delivery of liposomal drugs to solid tumors based on EPR effects.
Maruyama K
Adv Drug Deliv Rev; 2011 Mar; 63(3):161-9. PubMed ID: 20869415
[TBL] [Abstract][Full Text] [Related]
10. [Nanostructured liposomal systems as transport agents for anticancer drugs].
Baryshnikov AIu
Vestn Ross Akad Med Nauk; 2012; (3):23-31. PubMed ID: 22712271
[TBL] [Abstract][Full Text] [Related]
11. Combination therapy with metronomic S-1 dosing and oxaliplatin-containing PEG-coated cationic liposomes in a murine colorectal tumor model: synergy or antagonism?
Abu Lila AS; Okada T; Doi Y; Ichihara M; Ishida T; Kiwada H
Int J Pharm; 2012 Apr; 426(1-2):263-270. PubMed ID: 22310465
[TBL] [Abstract][Full Text] [Related]
12. Antineovascular therapy with angiogenic vessel-targeted polyethyleneglycol-shielded liposomal DPP-CNDAC.
Asai T; Miyazawa S; Maeda N; Hatanaka K; Katanasaka Y; Shimizu K; Shuto S; Oku N
Cancer Sci; 2008 May; 99(5):1029-33. PubMed ID: 18294280
[TBL] [Abstract][Full Text] [Related]
13. Tumor growth inhibition through targeting liposomally bound curcumin to tumor vasculature.
Mondal G; Barui S; Saha S; Chaudhuri A
J Control Release; 2013 Dec; 172(3):832-40. PubMed ID: 24036260
[TBL] [Abstract][Full Text] [Related]
14. Hyperthermia and thermosensitive liposomes for improved delivery of chemotherapeutic drugs to solid tumors.
Koning GA; Eggermont AM; Lindner LH; ten Hagen TL
Pharm Res; 2010 Aug; 27(8):1750-4. PubMed ID: 20424894
[TBL] [Abstract][Full Text] [Related]
15. Effect of the surface charge of liposomes on their uptake by angiogenic tumor vessels.
Krasnici S; Werner A; Eichhorn ME; Schmitt-Sody M; Pahernik SA; Sauer B; Schulze B; Teifel M; Michaelis U; Naujoks K; Dellian M
Int J Cancer; 2003 Jul; 105(4):561-7. PubMed ID: 12712451
[TBL] [Abstract][Full Text] [Related]
16. Multiple administration of PEG-coated liposomal oxaliplatin enhances its therapeutic efficacy: a possible mechanism and the potential for clinical application.
Abu Lila AS; Eldin NE; Ichihara M; Ishida T; Kiwada H
Int J Pharm; 2012 Nov; 438(1-2):176-83. PubMed ID: 22944302
[TBL] [Abstract][Full Text] [Related]
17. Enhanced permeability and retention of macromolecular drugs in solid tumors: a royal gate for targeted anticancer nanomedicines.
Greish K
J Drug Target; 2007; 15(7-8):457-64. PubMed ID: 17671892
[TBL] [Abstract][Full Text] [Related]
18. Thioaptamer conjugated liposomes for tumor vasculature targeting.
Mann AP; Bhavane RC; Somasunderam A; Liz Montalvo-Ortiz B; Ghaghada KB; Volk D; Nieves-Alicea R; Suh KS; Ferrari M; Annapragada A; Gorenstein DG; Tanaka T
Oncotarget; 2011 Apr; 2(4):298-304. PubMed ID: 21666286
[TBL] [Abstract][Full Text] [Related]
19. Tumor-type-dependent vascular permeability constitutes a potential impediment to the therapeutic efficacy of liposomal oxaliplatin.
Abu Lila AS; Matsumoto H; Doi Y; Nakamura H; Ishida T; Kiwada H
Eur J Pharm Biopharm; 2012 Aug; 81(3):524-31. PubMed ID: 22554766
[TBL] [Abstract][Full Text] [Related]
20. Targeted thermosensitive liposomes: an attractive novel approach for increased drug delivery to solid tumors.
Dicheva BM; Koning GA
Expert Opin Drug Deliv; 2014 Jan; 11(1):83-100. PubMed ID: 24320104
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
